Proportion of participants with type 2 diabetes achieving a metabolic composite endpoint with once‐weekly semaglutide treatment versus comparators: Post hoc pooled analysis from SUSTAIN 1‐5, 7‐10 and SUSTAIN China.

Autor: Ji, Linong, Ahmann, A. J., Ahrén, B., Capehorn, M. S., Hu, P., Lingvay, I., Liu, W., Rodbard, H. W., Shen, Z., Sorli, C.

Publikováno v: Diabetes, Obesity & Metabolism; Jan2024, Vol. 26 Issue 1, p233-241, 9p

Sotagliflozin added to optimized insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: A pooled analysis of inTandem1 and inTandem2

Autor: Rodbard, H. W., Giaccari, Andrea, Lajara, R., Stewart, J., Strumph, P. S., Oliveira, J., Lapuerta, P., Castro, R.

Publikováno v: Diabetes, obesitymetabolismREFERENCES. 22(11)

To evaluate whether the addition of sotagliflozin to optimized insulin significantly increases the proportion of adults with type 1 diabetes who achieve HbA1c goals without weight gain.In a patient-level pooled analysis (n = 1575) of data from two ph

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::7f945d4d5024ed6ca015d52c6e385d00
https://pubmed.ncbi.nlm.nih.gov/32618383

Weight loss induced by semaglutide once weekly contributes to improved health-related quality of life and treatment satisfaction

Autor: John Wilding, Rodbard, H. W., Uusinarkaus, K. T., Gaal, L., Hansen, T., Sandberg, A. M. L., Tadayon, S., Davies, M. J.

Publikováno v: DIABETOLOGIA
Publons

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::5706a91d017425a2c290020a6ef8e2c4

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Comparison of insulin degludec with insulin glargine in insulin‐naive subjects with Type 2 diabetes: a 2‐year randomized, treat‐to‐target trial

Autor: Rodbard, H W, Cariou, B, Zinman, B, Handelsman, Y, Philis-Tsimikas, A, Skjøth, T V, Rana, A, Mathieu, Christopher John, Gram, Jeppe

Publikováno v: Rodbard, H W, Cariou, B, Zinman, B, Handelsman, Y, Philis-Tsimikas, A, Skjøth, T V, Rana, A, Mathieu, C J, BEGIN Once Long trial investigators & Gram, J 2013, ' Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes : a 2-year randomized, treat-to-target trial ', Diabetic Medicine Online, vol. 30, no. 11, pp. 1298-1304 . https://doi.org/10.1111/dme.12303
Diabetic Medicine

Aims The aim of this study was to compare long-term safety and efficacy of the basal insulin analogue degludec with glargine in insulin-naive subjects with Type 2 diabetes. Methods This open-label trial included a 52-week core period followed by a 52

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2474e82cb3513fbd297ea71b35e4c0b9
https://doi.org/10.1111/dme.12303